CoChat

Toward Directing Opioid Receptor Signaling to Refine Opioid Therapeutics

Open access
Grim, Travis W., Acevedo-Canabal, Agnes, Bohn, Laura M. · 2020 · Biological Psychiatry
Cited by 85

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

The mu opioid receptor (MOR) is a diversely regulated target for the alleviation of pain in the clinical setting. However, untoward side effects such as tolerance, dependence, respiratory suppression, constipation, and abuse liability detract from their usefulness. Studies in genetically modified rodent models suggest that activating G protein signaling pathways while avoiding phosphorylation of the receptor or recruitment of βarrestin scaffolding proteins could preserve the analgesic properties of MOR agonists while avoiding certain side effects. With the development of novel MOR “biased” agonists, which lead to preferential activation of G protein pathways over receptor phosphorylation, internalization or interaction with other effectors, this hypothesis can be tested in a native, physiological setting. Overall, it is clear that the MOR is not a simple on and off switch and that the diverse means by which the receptor can be regulated may present an opportunity to refine therapeutics for the treatment of pain.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.biopsych.2019.10.020

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 57

  1. Pasternak, 2018, Mu opioid pharmacology: 40 Years to the promised land, Adv Pharmacol, 82, 261, 10.1016/bs.apha.2017.09.006 · DOI
  2. Volkow, 2017, The role of science in addressing the opioid crisis, N Engl J Med, 377, 391, 10.1056/NEJMsr1706626 · DOI · Paper page
  3. Shukla, 2014, Visualization of arrestin recruitment by a G-protein-coupled receptor, Nature, 512, 218, 10.1038/nature13430 · DOI · Paper page
  4. Gurevich, 2019, The structural basis of the arrestin binding to GPCRs, Mol Cell Endocrinol, 484, 34, 10.1016/j.mce.2019.01.019 · DOI
  5. Thomsen, 2016, GPCR-G protein-beta-arrestin super-complex mediates sustained G protein signaling, Cell, 166, 907, 10.1016/j.cell.2016.07.004 · DOI · Paper page
  6. Bohn, 1999, Enhanced morphine analgesia in mice lacking beta-arrestin 2, Science, 286, 2495, 10.1126/science.286.5449.2495 · DOI · Paper page
  7. Bohn, 2000, Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence, Nature, 408, 720, 10.1038/35047086 · DOI · Paper page
  8. Bohn, 2004, Relative opioid efficacy is determined by the complements of the G protein-coupled receptor desensitization machinery, Mol Pharmacol, 66, 106, 10.1124/mol.66.1.106 · DOI · Paper page
  9. Bohn, 2002, Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice, J Neurosci, 22, 10494, 10.1523/JNEUROSCI.22-23-10494.2002 · DOI · Paper page
  10. Mittal, 2012, Evidence that behavioral phenotypes of morphine in beta-arr2-/- mice are due to the unmasking of JNK signaling, Neuropsychopharmacology, 37, 1953, 10.1038/npp.2012.42 · DOI
  11. Bu, 2015, Enhancement of morphine analgesia and prevention of morphine tolerance by downregulation of beta-arrestin 2 with antigene RNAs in mice, Int J Neurosci, 125, 56, 10.3109/00207454.2014.896913 · DOI
  12. Li, 2009, Improvement of morphine-mediated analgesia by inhibition of beta--arrestin-2 expression in mice periaqueductal gray matter, Int J Mol Sci, 10, 954, 10.3390/ijms10030954 · DOI · Paper page
  13. Yang, 2011, Antinociceptive potentiation and attenuation of tolerance by intrathecal beta-arrestin 2 small interfering RNA in rats, Br J Anaesth, 107, 774, 10.1093/bja/aer291 · DOI
  14. Butcher, 2011, Differential G-protein-coupled receptor phosphorylation provides evidence for a signaling bar code, J Biol Chem, 286, 11506, 10.1074/jbc.M110.154526 · DOI · Paper page
  15. Mayer, 2019, Distinct G protein-coupled receptor phosphorylation motifs modulate arrestin affinity and activation and global conformation, Nat Commun, 10, 1261, 10.1038/s41467-019-09204-y · DOI
  16. Gainetdinov, 2004, Desensitization of G protein-coupled receptors and neuronal functions, Annu Rev Neurosci, 27, 107, 10.1146/annurev.neuro.27.070203.144206 · DOI · Paper page
  17. Glück, 2014, Loss of morphine reward and dependence in mice lacking G protein-coupled receptor kinase 5, Biol Psychiatry, 76, 767, 10.1016/j.biopsych.2014.01.021 · DOI
  18. Raehal, 2009, Morphine-induced physiological and behavioral responses in mice lacking G protein-coupled receptor kinase 6, Drug Alcohol Depend, 104, 187, 10.1016/j.drugalcdep.2009.04.011 · DOI
  19. Kliewer, 2019, Phosphorylation-deficient G-protein-biased mu-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects, Nat Commun, 10, 367, 10.1038/s41467-018-08162-1 · DOI · Paper page
  20. Xu, 2017, Alternatively spliced mu opioid receptor C termini impact the diverse actions of morphine, J Clin Invest, 127, 1561, 10.1172/JCI88760 · DOI · Paper page
  21. Raehal, 2011, The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics, Neuropharmacology, 60, 58, 10.1016/j.neuropharm.2010.08.003 · DOI · Paper page
  22. Terman, 2004, G-protein receptor kinase 3 (GRK3) influences opioid analgesic tolerance but not opioid withdrawal, Br J Pharmacol, 141, 55, 10.1038/sj.bjp.0705595 · DOI · Paper page
  23. Grecksch, 2011, Analgesic tolerance to high-efficacy agonists but not to morphine is diminished in phosphorylation-deficient S375A mu-opioid receptor knock-in mice, J Neurosci, 31, 13890, 10.1523/JNEUROSCI.2304-11.2011 · DOI
  24. Groer, 2011, Agonist-directed interactions with specific beta-arrestins determine mu-opioid receptor trafficking, ubiquitination, and dephosphorylation, J Biol Chem, 286, 31731, 10.1074/jbc.M111.248310 · DOI · Paper page
  25. Thompson, 2015, Biased agonism of endogenous opioid peptides at the mu-opioid receptor, Mol Pharmacol, 88, 335, 10.1124/mol.115.098848 · DOI
  26. Whistler, 1998, Morphine-activated opioid receptors elude desensitization by beta-arrestin, Proc Natl Acad Sci U S A, 95, 9914, 10.1073/pnas.95.17.9914 · DOI · Paper page
  27. Zhang, 1998, Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness, Proc Natl Acad Sci U S A, 95, 7157, 10.1073/pnas.95.12.7157 · DOI · Paper page
  28. Wood, 2004, Function of opioids in the enteric nervous system, Neurogastroenterol Motil, 16, 17, 10.1111/j.1743-3150.2004.00554.x · DOI · Paper page
  29. Briggs, 1995, Oxymorphone-induced analgesia and colonic motility measured in colorectal distension, Pharmacol Biochem Behav, 52, 561, 10.1016/0091-3057(95)00140-R · doi:10.1016/0091-3057(95)00140-r
  30. Burks, 1987, Brain, spinal cord and peripheral sites of action of enkephalins and other endogenous opioids on gastrointestinal motility, Gastroenterol Clin Biol, 11, 44B
  31. Raehal, 2005, Morphine side effects in beta-arrestin 2 knockout mice, J Pharmacol Exp Ther, 314, 1195, 10.1124/jpet.105.087254 · DOI · Paper page
  32. Maguma, 2014, Specific localization of beta--arrestin-2 in myenteric plexus of mouse gastrointestinal tract, PLoS One, 9, 10.1371/journal.pone.0103894 · doi:10.1371/journal.pone.0103894
  33. Smith, 2012, Morphine decreases enteric neuron excitability via inhibition of sodium channels, PLoS One, 7, 10.1371/journal.pone.0045251 · DOI
  34. Bohn, 2003, Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice, J Neurosci, 23, 10265, 10.1523/JNEUROSCI.23-32-10265.2003 · DOI · Paper page
  35. Urs, 2011, A dopamine D1 receptor-dependent beta-arrestin signaling complex potentially regulates morphine-induced psychomotor activation but not reward in mice, Neuropsychopharmacology, 36, 551, 10.1038/npp.2010.186 · DOI · Paper page
  36. Beaulieu, 2005, An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior, Cell, 122, 261, 10.1016/j.cell.2005.05.012 · DOI · Paper page
  37. Schmid, 2010, Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via β-arrestin2/Src/Akt signaling complex in vivo, J Neurosci, 30, 13513, 10.1523/JNEUROSCI.1665-10.2010 · DOI · Paper page
  38. Masri, 2008, Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics, Proc Natl Acad Sci U S A, 105, 13656, 10.1073/pnas.0803522105 · DOI · Paper page
  39. Watari, 2014, Multiple functions of G protein-coupled receptor kinases, J Mol Signal, 9, 1
  40. Stoeber, 2018, A genetically encoded biosensor reveals location bias of opioid drug action, Neuron, 98, 963, 10.1016/j.neuron.2018.04.021 · DOI · Paper page
  41. Groer, 2007, An opioid agonist that does not induce mu-opioid receptor--arrestin interactions or receptor internalization, Mol Pharmacol, 71, 549, 10.1124/mol.106.028258 · DOI · Paper page
  42. Lamb, 2012, Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: New concepts in mu opioid receptor pharmacology: From a symposium on new concepts in mu-opioid pharmacology, Drug Alcohol Depend, 121, 181, 10.1016/j.drugalcdep.2011.10.026 · DOI
  43. Tidgewell, 2008, Herkinorin analogues with differential beta-arrestin-2 interactions, J Med Chem, 51, 2421, 10.1021/jm701162g · DOI
  44. Manglik, 2016, Structure-based discovery of opioid analgesics with reduced side effects, Nature, 537, 185, 10.1038/nature19112 · DOI · Paper page
  45. Chen, 2013, Structure-activity relationships and discovery of a G protein biased mu opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan- 9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain, J Med Chem, 56, 8019, 10.1021/jm4010829 · DOI · Paper page
  46. Austin Zamarripa, 2018, The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats, Drug Alcohol Depend, 192, 158, 10.1016/j.drugalcdep.2018.08.002 · DOI
  47. Liang, 2019, Pharmacological characters of oliceridine, a mu-opioid receptor G-protein-biased ligand in mice, Anesth Analg, 129, 1414, 10.1213/ANE.0000000000003662 · DOI
  48. Soergel, 2014, Biased agonism of the mu-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers, Pain, 155, 1829, 10.1016/j.pain.2014.06.011 · DOI · Paper page
  49. Soergel, 2014, First clinical experience with TRV130: Pharmacokinetics and pharmacodynamics in healthy volunteers, J Clin Pharmacol, 54, 351, 10.1002/jcph.207 · DOI
  50. Singla, 2017, A randomized, Phase IIb study investigating oliceridine (TRV130), a novel micro-receptor G-protein pathway selective (mu-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty, J Pain Res, 10, 2413
  51. Singla, 2019, APOLLO-2: A randomized, placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the mu-opioid receptor, for management of moderate to severe acute pain following abdominoplasty, Pain Pract, 19, 715, 10.1111/papr.12801 · DOI · Paper page
  52. Hill, 2018, The novel mu-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception, Br J Pharmacol, 175, 2653, 10.1111/bph.14224 · DOI · Paper page
  53. Varadi, 2016, Mitragynine/corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit beta-arrestin-2, J Med Chem, 59, 8381, 10.1021/acs.jmedchem.6b00748 · DOI · Paper page
  54. Black, 1983, Operational models of pharmacological agonism, Proc R Soc Lond B Biol Sci, 220, 141, 10.1098/rspb.1983.0093 · DOI · Paper page
  55. Grim, 2019, A G protein signaling-biased agonist at the μ-opioid receptor reverses morphine tolerance while preventing morphine withdrawal [published online ahead of print Aug 23], Neuropsychopharmacology
  56. Schwienteck, 2019, Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats, Neuropharmacology, 150, 200, 10.1016/j.neuropharm.2019.01.020 · DOI
  57. Ho, 2018, G protein signaling-biased agonism at the kappa-opioid receptor is maintained in striatal neurons, Sci Signal, 11, 10.1126/scisignal.aar4309 · DOI

Cited by

See all 85

Metadata

Authors
Grim, T. W., Acevedo-Canabal, A., & Bohn, L. M.
Venue
Biological Psychiatry
Publisher
Elsevier BV
Published
2020-01
Volume
87
Issue
1
Pages
15-21
ISSN
0006-3223 (ISSN-L)
OpenAlex
W2982315497
Cited by
85
References
7
FWCI
4.01
Type
journal article
Language
en
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
National Institute on Drug Abuse (DA038964, DA033073, DA047039)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Toward Directing Opioid Receptor Signaling to Refine Opioid Therapeutics. https://app.cochat.ai/papers/10.1016/j.biopsych.2019.10.020
The paper
Grim, T. W., Acevedo-Canabal, A., & Bohn, L. M. (2020). Toward Directing Opioid Receptor Signaling to Refine Opioid Therapeutics. Biological Psychiatry. https://doi.org/10.1016/j.biopsych.2019.10.020

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.